Data / Research funding / Emphysema
Emphysema: 114 NIH awards ($3.1B) to 38 organizations
114 NIH awards ($3.1B) in the NIH spending category Emphysema, to 38 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
114 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NIEHS - Lung Microbiome Promotes Emphysema by Activating Lung Innate Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,960,824,321 | August 31, 2025 | August 30, 2026 | BRISCOE, LYNN | reporter.nih.gov |
| Precision phenotyping of emphysema in the elderly: the MESA Lung Study | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $6,794,185 | August 2, 2004 | January 31, 2027 | BARR, R GRAHAM | reporter.nih.gov |
| (1 of 2) Genetic Epidemiology of COPD | NIH | National Heart, Lung, and Blood Institute | 2021 | $6,661,979 | September 27, 2007 | July 31, 2023 | CRAPO, JAMES D | reporter.nih.gov |
| Understanding the Origins of Early COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $6,605,820 | May 1, 2020 | April 30, 2025 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $5,484,720 | September 20, 2021 | August 31, 2026 | KANER, ROBERT J | reporter.nih.gov |
| Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,258,583 | August 20, 2020 | June 30, 2026 | D'ARMIENTO, JEANINE M | reporter.nih.gov |
| Combined Cardiopulmonary Failure in COPD: SPIROMICS HF | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $4,223,234 | August 28, 2008 | June 30, 2025 | BARR, R GRAHAM | reporter.nih.gov |
| Mesenchymal Vascular Progenitor Depletion Promotes Lung Aging and Susceptibility to Emphysema | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,964,079 | January 1, 2022 | December 31, 2028 | MAJKA, SUSAN M | reporter.nih.gov |
| 2/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,669,568 | September 17, 2021 | August 31, 2026 | SPINO, CATHERINE A | reporter.nih.gov |
| SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression | NIH | National Heart, Lung, and Blood Institute | 2021 | $3,589,191 | September 15, 2017 | November 30, 2024 | WOODRUFF, PRESCOTT G | reporter.nih.gov |
| Role of MIF and CD74 in the pathogenesis of emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,410,379 | January 1, 2021 | December 31, 2026 | BUCALA, RICHARD J | reporter.nih.gov |
| Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,409,256 | February 15, 2021 | January 31, 2027 | OELSNER, ELIZABETH | reporter.nih.gov |
| Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,344,916 | July 1, 2015 | April 30, 2026 | HUANG, LAURENCE | reporter.nih.gov |
| Hepatocyte Growth Factor Signaling and Airspace Maintenance | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,997,638 | September 1, 2021 | May 31, 2026 | NEPTUNE, ENID R | reporter.nih.gov |
| Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,937,551 | April 15, 2022 | March 31, 2027 | WASHKO, GEORGE R | reporter.nih.gov |
| Using Integrative Genomics To Identify and Characterize Emphysema-Associated eQTL | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,744,141 | September 1, 2014 | May 31, 2026 | CASTALDI, PETER | reporter.nih.gov |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI | NIH | National Cancer Institute | 2021 to 2025 | $2,741,941 | September 17, 2021 | August 31, 2027 | RUSET, IULIAN CONSTANTIN | reporter.nih.gov |
| Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,711,888 | April 1, 2021 | March 31, 2025 | MCNITT-GRAY, MICHAEL F | reporter.nih.gov |
| B cell-adaptive Immune Profile in Emphysema-predominant COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,670,764 | September 1, 2020 | August 31, 2025 | POLVERINO, FRANCESCA | reporter.nih.gov |
| Ceramide-Induced Destruction in Emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,661,589 | July 1, 2006 | April 30, 2025 | PETRACHE, IRINA | reporter.nih.gov |
| Imaging the functional response of the lung to bronchoscopic lung volume reduction | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,659,733 | August 10, 2022 | July 31, 2027 | RIZI, RAHIM R | reporter.nih.gov |
| Imaging and multi-omics analyses to identify molecular subtypes of distinct emphysema patterns | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,605,661 | September 1, 2023 | July 31, 2028 | EL BOUEIZ, ADEL | reporter.nih.gov |
| Gene Therapy for Alpha 1-Antitrypsin Deficiency | NIH | National Heart, Lung, and Blood Institute | 2025 | $2,505,334 | May 15, 2024 | April 30, 2028 | CRYSTAL, RONALD G | reporter.nih.gov |
| (2 of 2) Genetic Epidemiology of COPD | NIH | National Heart, Lung, and Blood Institute | 2021 | $2,362,897 | September 27, 2007 | July 31, 2023 | SILVERMAN, EDWIN K | reporter.nih.gov |
| Multi-omic networks associated with COPD progression in TOPMed Cohorts | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,263,919 | April 5, 2020 | March 31, 2026 | KECHRIS-MAYS, KATHERINA | reporter.nih.gov |
| Sexual dimorphism in susceptibility to emphysematous tissue injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,217,911 | June 1, 2023 | May 31, 2027 | SHIM, YUN MICHAEL | reporter.nih.gov |
| Regulatory roles of peptidylarginine deimination in elastogenisis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,172,338 | April 15, 2022 | March 31, 2026 | HO, I-CHENG | reporter.nih.gov |
| Structural Determinants of Disease Progression in COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,086,195 | April 5, 2020 | March 31, 2026 | BHATT, SURYA P. | reporter.nih.gov |
| Prognostic Markers of Emphysema Progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,075,083 | March 15, 2020 | February 28, 2026 | SAN JOSE ESTEPAR, RAUL | reporter.nih.gov |
| Loss of progenitor function accelerates lung aging | NIH | National Institute on Aging | 2023 to 2025 | $2,062,620 | June 15, 2023 | February 29, 2028 | MAJKA, SUSAN M | reporter.nih.gov |
| The Role of Adenine Nucleotide Translocase in Mitochondrial Dysfunction Associated Senescence in Chronic Obstructive Pulmonary Disease (COPD) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,059,255 | August 1, 2023 | April 30, 2028 | KLIMENT, CORRINE R | reporter.nih.gov |
| Prediction of COPD Progression by PRM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,058,675 | March 15, 2020 | February 28, 2025 | HAN, MEILAN K | reporter.nih.gov |
| Integrative Characterization on the function of COPD GWAS gene, HHIP | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,966,527 | April 5, 2020 | March 31, 2025 | ZHOU, ANNY XIAOBO | reporter.nih.gov |
| Endobronchial Supervalve for the Treatment of Emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,919,606 | December 1, 2020 | November 30, 2024 | GELFAND, MARK | reporter.nih.gov |
| Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,919,203 | July 6, 2020 | June 30, 2025 | NEPTUNE, ENID R | reporter.nih.gov |
| Role of FBXO24 mediated ubiquitination of FoxP1 protein in the pathogenesis and treatment of COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,874,669 | July 15, 2020 | June 30, 2025 | CHANDRA, DIVAY | reporter.nih.gov |
| Mechanisms of DNA damage induced emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,827,951 | July 15, 2014 | May 31, 2025 | ARMANIOS, MARY Y | reporter.nih.gov |
| Integrated Analysis of Microbial and Genomic data in Obstructive Lung Disease (I AM GOLD) Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,595,582 | September 15, 2019 | July 31, 2025 | HUANG, LAURENCE | reporter.nih.gov |
| The Penn LungMAP 3 team: Defining chronic lung disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,569,484 | September 1, 2024 | August 31, 2029 | MORRISEY, EDWARD E | reporter.nih.gov |
| A multi-scale computational model of the extracellular matrix of the lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,533,586 | June 1, 2018 | May 31, 2024 | SUKI, BELA | reporter.nih.gov |
| Protective effects of metformin against cigarette smoke-induced lung pathologies via regulation of fatty acids metabolism | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,492,860 | August 1, 2024 | July 31, 2028 | POLVERINO, FRANCESCA | reporter.nih.gov |
| A Pathogenic Smoke Associated Neutrophilic Exosomal Pathway. | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,485,000 | May 1, 2022 | April 30, 2027 | GENSCHMER, KRISTOPHER R. | reporter.nih.gov |
| Novel Quantitative Emphysema Subtypes in MESA and SPIROMICS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,458,595 | August 1, 2014 | April 30, 2025 | BARR, R GRAHAM | reporter.nih.gov |
| Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,438,354 | January 15, 2024 | December 31, 2027 | SERBAN, KARINA | reporter.nih.gov |
| 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,432,888 | September 20, 2021 | August 31, 2022 | KANER, ROBERT J | reporter.nih.gov |
| Defining the Role of Viral Infections and Autoantibodies in Chronic Obstructive Pulmonary Disease Progression | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,344,350 | July 16, 2024 | April 30, 2028 | RUCZINSKI, INGO | reporter.nih.gov |
| Leveraging Quantitative Imaging from Lung Cancer Screening to Create Tools to Confront COPD | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,299,221 | September 1, 2024 | July 31, 2028 | HAN, MEILAN K | reporter.nih.gov |
| Role of TACC2 in smoking-induced COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,181,575 | February 15, 2020 | December 31, 2024 | NYUNOYA, TORU | reporter.nih.gov |
| Integrating Multi-Modal Data and Biomechanics in COPD: Toward Robust and Interpretable Biomarkers for Disease Subtyping and Progression | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,163,790 | May 1, 2018 | February 28, 2030 | BATMANGHELICH, KAYHAN | reporter.nih.gov |
| Novel Vector Platform for Gene Therapy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,146,366 | July 1, 2019 | March 31, 2024 | CURIEL, DAVID TERRY | reporter.nih.gov |
| Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,119,330 | June 1, 2020 | March 3, 2023 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| Chymotrypsin-like Elastase 1 in Lung Development and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,058,322 | April 15, 2018 | March 31, 2024 | ZINGARELLI, BASILIA | reporter.nih.gov |
| Non-canonical WNT signaling in emphysema and lung regeneration | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,027,860 | February 1, 2019 | April 30, 2025 | KOENIGSHOFF, MELANIE | reporter.nih.gov |
| An Early Imaging Marker of Emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $949,062 | May 28, 2019 | April 30, 2024 | GALBAN, CRAIG J | reporter.nih.gov |
| Biomarker of Lung Disease in African Americans | NIH | National Heart, Lung, and Blood Institute | 2021 | $934,082 | August 15, 2018 | May 31, 2023 | BOWLER, RUSSELL PAUL | reporter.nih.gov |
| Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $933,377 | July 15, 2020 | June 30, 2022 | D'ARMIENTO, JEANINE M | reporter.nih.gov |
| AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease | NIH | National Center for Advancing Translational Sciences | 2021 | $896,654 | April 9, 2018 | August 31, 2023 | DRANSFIELD, MARK T | reporter.nih.gov |
| MECHANISM AND FUNCTION OF LET-7, A NOVEL MODULATOR OF TH17-DEPENDENT EMPHYSEMA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $803,002 | September 1, 2018 | August 31, 2023 | CORRY, DAVID B | reporter.nih.gov |
| Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics | NIH | National Heart, Lung, and Blood Institute | 2021 | $786,595 | January 15, 2017 | December 31, 2023 | SHIM, YUN MICHAEL | reporter.nih.gov |
| Developing Lithium as a Disease-Modifying Therapy for Emphysema Using a Precision Medicine Approach | NIH | National Heart, Lung, and Blood Institute | 2025 | $761,346 | September 15, 2025 | June 30, 2030 | CHANDRA, DIVAY | reporter.nih.gov |
| Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema | NIH | National Heart, Lung, and Blood Institute | 2023 | $760,358 | July 1, 2023 | September 14, 2023 | SERBAN, KARINA | reporter.nih.gov |
| Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $753,750 | May 27, 2013 | December 31, 2023 | FLOTTE, TERENCE R. | reporter.nih.gov |
| Resolution of Epithelial Cell Hyperplasia in Asthma | NIH | National Heart, Lung, and Blood Institute | 2021 | $724,538 | July 1, 2003 | May 31, 2024 | TESFAIGZI, YOHANNES | reporter.nih.gov |
| Defining cardinal functions of lung progenitors during regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $701,795 | September 1, 2025 | June 30, 2029 | MORRISEY, EDWARD E | reporter.nih.gov |
| Leveraging Serum Metabolomics to Understand Clinical Phenotypes in COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $699,840 | July 1, 2020 | October 31, 2025 | LABAKI, WASSIM W | reporter.nih.gov |
| Suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema | NIH | National Heart, Lung, and Blood Institute | 2025 | $684,814 | January 1, 2025 | November 30, 2028 | PENG, TIEN | reporter.nih.gov |
| The role of COPD genetic risk factor HHIP on lymphocytic inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $678,240 | April 1, 2020 | March 31, 2026 | YUN, JEONG H | reporter.nih.gov |
| Maintenance of the alveolar niche in emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 | $676,835 | August 22, 2018 | June 30, 2022 | PENG, TIEN | reporter.nih.gov |
| Activated Neutrophilic Exosome as Biomarker and Therapeutic Target in COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $658,584 | June 15, 2020 | May 31, 2026 | RUSSELL, DEREK | reporter.nih.gov |
| An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $650,726 | May 1, 2018 | December 31, 2022 | BATMANGHELICH, KAYHAN | reporter.nih.gov |
| Role of Lung MSC in Emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 | $616,754 | March 21, 2019 | December 31, 2021 | MAJKA, SUSAN M | reporter.nih.gov |
| Defining Pathways in COPD Patient Oriented Research | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $610,152 | July 1, 2017 | July 31, 2027 | HAN, MEILAN K | reporter.nih.gov |
| Mechanism of pathogenic macrophage activation in emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 | $597,019 | February 1, 2018 | January 31, 2023 | MITZNER, WAYNE | reporter.nih.gov |
| The Pulmonary Vasculature and Platelets in Emphysema and COPD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $589,493 | May 1, 2019 | April 30, 2025 | PISTENMAA, CARRIE L | reporter.nih.gov |
| Statistical Standardization of CT for the Analysis of Parenchymal Injury Progression in Smokers | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $563,760 | August 1, 2019 | January 12, 2025 | VEGAS SANCHEZ-FERRERO, GONZALO | reporter.nih.gov |
| The role of endothelial derived Leucine-Rich Alpha-2-Glycoprotein 1 (LRG1) in the pathogenesis of COPD | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $505,440 | August 1, 2022 | July 31, 2027 | RACANELLI, ALEXANDRA CHRISTIN | reporter.nih.gov |
| Silent Zones of Lung Disease in COPD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $504,411 | January 1, 2023 | December 31, 2027 | BODDULURI, SANDEEP | reporter.nih.gov |
| The Role of Airway Morphology in Environmental LungDiseases | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $500,901 | September 1, 2019 | August 31, 2025 | SACK, CORALYNN SHAYNA | reporter.nih.gov |
| Postnatal Alveolar Formation | NIH | National Heart, Lung, and Blood Institute | 2021 | $498,360 | September 1, 2018 | July 31, 2024 | MINOO, PARVIZ MINOO | reporter.nih.gov |
| Managing the Folding Landscape in Alpha1 Liver-Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $483,750 | July 15, 2018 | April 30, 2023 | BALCH, WILLIAM EDWARD | reporter.nih.gov |
| Mannose binding lectin-dependent complement activation in emphysema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $475,956 | December 17, 2018 | November 30, 2023 | SERBAN, KARINA | reporter.nih.gov |
| Novel Technologies for Detection and Monitoring of Lung Disease | NIH | National Library of Medicine | 2025 | $471,544 | September 16, 2025 | September 15, 2026 | BHATT, SHIV KUMAR | reporter.nih.gov |
| Development of PAR2 Pepducins for the Treatment of COPD | NIH | National Heart, Lung, and Blood Institute | 2025 | $468,369 | September 15, 2025 | October 31, 2026 | COVIC, LIDIJA | reporter.nih.gov |
| Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma | NIH | National Heart, Lung, and Blood Institute | 2021 | $465,888 | September 20, 2018 | August 31, 2023 | CHU, HONG W | reporter.nih.gov |
| Complement driven innate and adaptive autoreactivity in lung transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 | $444,968 | March 3, 2021 | June 30, 2025 | ATKINSON, CARL | reporter.nih.gov |
| The Pulmonary Lymphatics in Inflammation and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $429,672 | July 23, 2019 | June 30, 2024 | REED, HASINA OUTTZ | reporter.nih.gov |
| Gene Therapy for Alpha 1-Antitrypsin Deficiency | NIH | National Heart, Lung, and Blood Institute | 2024 | $422,895 | May 15, 2024 | April 30, 2025 | CRYSTAL, RONALD G | reporter.nih.gov |
| The role of PUMA in the progression of cigarette smoking-induced COPD | NIH | National Heart, Lung, and Blood Institute | 2023 | $413,958 | September 22, 2023 | August 31, 2025 | CHEN, DONGSHI | reporter.nih.gov |
| Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $341,278 | July 1, 2018 | October 31, 2023 | EL BOUEIZ, ADEL | reporter.nih.gov |
| Leukotriene B4 and IL-8 in alpha-1 heterozygotes (PI*MZ genotype) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $341,121 | April 1, 2024 | March 31, 2029 | TEJWANI, VICKRAM | reporter.nih.gov |
| Characterization of Early Response to Chronic Lung Injury using Chest CT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $340,640 | January 1, 2019 | December 3, 2022 | ASH, SAMUEL | reporter.nih.gov |
| Loss of progenitor function accelerates lung aging | NIH | National Institute on Aging | 2021 | $336,200 | September 1, 2021 | June 14, 2023 | MAJKA, SUSAN M | reporter.nih.gov |
| Sex chromosome gene regulatory networks and COPD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $324,000 | May 1, 2023 | February 28, 2025 | LOPES-RAMOS, CAMILA | reporter.nih.gov |
| Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | NIH | National Heart, Lung, and Blood Institute | 2022 | $321,866 | February 5, 2022 | May 31, 2024 | GLASS, CHARLES ALEXANDER | reporter.nih.gov |
| Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin | NIH | National Heart, Lung, and Blood Institute | 2022 | $274,441 | September 22, 2022 | September 21, 2024 | LEWIS, NATHAN ENOCH | reporter.nih.gov |
| Robust Detection of Early Small Airway Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $268,500 | March 1, 2021 | January 12, 2025 | VEGAS SANCHEZ-FERRERO, GONZALO | reporter.nih.gov |
| Role of specialized pro-resolving mediators of inflammation resolution in emphysema: analyses of SPIROMICS and LEEP | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $262,818 | August 1, 2024 | July 31, 2026 | BOSE, SONALI | reporter.nih.gov |
| Molecular Analysis of Airway Secretory Cells in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | February 21, 2025 | January 31, 2028 | HU, YAN | reporter.nih.gov |
| Isolated Abnormality in the Diffusion Capacity for Carbon Monoxide in People Living with HIV – Epidemiology, Etiology and Pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $240,190 | September 1, 2022 | June 30, 2025 | BYANOVA, KATERINA L. | reporter.nih.gov |
| Molecular Analysis of Airway Secretory Cells in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $217,138 | April 1, 2023 | February 20, 2025 | HU, YAN | reporter.nih.gov |
| Cigarette smoke influences alveolar type II cell-derived exosomes | NIH | National Institute of Environmental Health Sciences | 2021 | $197,088 | May 15, 2020 | October 31, 2023 | BAHMED, KARIM | reporter.nih.gov |
| Defining Combined Pulmonary Fibrosis and Emphysema (CPFE) using Quantitative CT Imaging | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $173,667 | September 10, 2024 | July 9, 2026 | WANG, JENNIFER MIN | reporter.nih.gov |
| Characterizing chronic lung disease in youth living with HIV: quantitative chest CT analyses | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $169,857 | April 1, 2022 | March 31, 2024 | ATTIA, ENGI FAROUK | reporter.nih.gov |
| MIF and DNA repair in the emphysematous lung | NIH | National Heart, Lung, and Blood Institute | 2021 | $168,480 | January 1, 2017 | December 31, 2021 | SAULER, MAOR | reporter.nih.gov |
| Assessment of microvascular volume in smokers using AI | NIH | National Heart, Lung, and Blood Institute | 2025 | $134,250 | February 1, 2025 | January 31, 2027 | NARDELLI, PIETRO | reporter.nih.gov |
| Pluripotent stem cell-based modeling of cigarette smoke injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $109,587 | April 1, 2020 | May 31, 2023 | ABO, KRISTINE | reporter.nih.gov |
| Early Changes of T2* Measures in Lung Tissues using deltaTE-UTE MRI on healthy and COPD Patients | NIH | National Heart, Lung, and Blood Institute | 2025 | $108,003 | August 15, 2025 | May 31, 2027 | MALIS, VADIM | reporter.nih.gov |
| Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $107,232 | January 1, 2024 | June 30, 2027 | MERRITT, CARLY | reporter.nih.gov |
| Phenotypes of Muscle Loss in Smokers | NIH | National Heart, Lung, and Blood Institute | 2022 | $79,168 | July 1, 2022 | June 30, 2023 | ZOU, RICHARD HANG | reporter.nih.gov |
| Identification of a Wnt/ Beta-catenin responsive adult lung epithelial progenitor cell for tissue repair in chronic lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $75,130 | August 1, 2019 | July 31, 2022 | HU, YAN | reporter.nih.gov |
| Allosteric Pharmacologic Chaperones for alpha-1 Antitrypsin Mutants | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $68,446 | February 1, 2022 | January 31, 2024 | GUERRERO, ADRIAN M. | reporter.nih.gov |
| Developing a novel adenine base editor tool for in vivo alpha-1 antitrypsin deficiency gene correction. | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $68,124 | September 1, 2024 | August 31, 2029 | GAO, JENNY | reporter.nih.gov |
| CT Characteristics of Emphysema for Evaluation of Pulmonary Nodules | NIH | National Heart, Lung, and Blood Institute | 2021 | $65,016 | August 1, 2021 | March 9, 2022 | KINSEY, CHARLES MATTHEW | reporter.nih.gov |
| B cell-adaptive Immune Profile in Emphysema-predominant COPD | NIH | National Heart, Lung, and Blood Institute | 2021 | $49,060 | September 1, 2020 | April 15, 2022 | POLVERINO, FRANCESCA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Leidos Biomedical Research, Inc. | Frederick, MD | 1 | $2.96 billion | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 6 | $21.1 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 16 | $20.8 million | 0 | $0 |
| National Jewish Health | Denver, CO | 10 | $18.9 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 7 | $17.4 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 6 | $10.1 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 7 | $9.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 5 | $8.7 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 7 | $7.6 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 5 | $5.6 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 3 | $5 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 3 | $4.9 million | 0 | $0 |
| Yale University | New Haven, CT | 2 | $3.6 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $3 million | 0 | $0 |
| Xemed, LLC | Durham, NH | 1 | $2.7 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 1 | $2.7 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 2 | $2.7 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 3 | $2.6 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $2.2 million | 0 | $0 |
| Coridea, LLC | New York, NY | 1 | $1.9 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $1.9 million | 0 | $0 |
| Washington University | Saint Louis, MO | 1 | $1.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 2 | $912,318 | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 2 | $821,874 | 0 | $0 |
| University of Washington | Seattle, WA | 2 | $670,758 | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 2 | $552,196 | 0 | $0 |
| Spiromatics, Inc. | Camden, DE | 1 | $471,544 | 0 | $0 |
| Oasis Pharmaceuticals | Lexington, MA | 1 | $468,369 | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 1 | $341,121 | 0 | $0 |
| Tega Therapeutics, Inc. | La Jolla, CA | 1 | $321,866 | 0 | $0 |
| Neuimmune Biologics, Inc. | Sykesville, MD | 1 | $274,441 | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 1 | $262,818 | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 1 | $249,000 | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 2 | $216,819 | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 1 | $197,088 | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 1 | $108,003 | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 1 | $65,016 | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $49,060 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 37 | $403,221,397 | 0 | $0 |
| 2024 | 43 | $539,225,883 | 0 | $0 |
| 2023 | 54 | $840,978,158 | 0 | $0 |
| 2022 | 63 | $649,935,532 | 0 | $0 |
| 2021 | 68 | $687,536,701 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.838 | December 3, 2026 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.838 | December 3, 2026 | Not listed | Same assistance listing 93.838 as 102 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.838 | December 4, 2026 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.838 | January 5, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.838 | January 5, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.838 | January 7, 2027 | $375,000 | Same assistance listing 93.838 as 102 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.838 | January 7, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-25-025 | NIH | 93.838 | February 3, 2027 | $1.5 million | Same assistance listing 93.838 as 102 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-25-026 | NIH | 93.838 | February 3, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-27-125 | NIH | 93.838 | February 16, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) | RFA-DK-27-108 | NIH | 93.838 | March 10, 2027 | $500,000 | Same assistance listing 93.838 as 102 awards here |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) | PAR-25-032 | NIH | 93.838 | March 16, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.838 | April 5, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.838 | April 5, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | RFA-OD-25-003 | NIH | 93.838 | April 9, 2027 | $200,000 | Same assistance listing 93.838 as 102 awards here |
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-26-002 | NIH | 93.838 | April 28, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-26-003 | NIH | 93.838 | April 28, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 102 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.